Drug Trial Radar · NCT07629544
A Study of DA-302168S in Participants With Overweight/Obesity
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
Jun 19, 2026
Primary completion
Jul 9, 2027
Study completion Oct 19, 2027
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University People's Hospital
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.
Conditions
- Overweight and Obesity
Interventions
DA-302168SDrug
A small molecule GLP-1R agonist tablet, orally administration, once daily
DA-302168SDrug
A small molecule GLP-1R agonist tablet, orally administration, once daily
PlaceboDrug
Matching placebo tablet will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in body weightTime frame: From baseline to week 40
- The proportion of subjects with a body weight reduction ≥5% from baselineTime frame: From baseline to week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.